Alivus Life Sciences Ltd · NSE:ALIVUS
Alivus Life Sciences — Q4 FY25 Earnings Presentation
21 slides from Alivus Life Sciences's earnings presentation, May 15, 2025
Slide 1: Exchange filing cover letter
May 15, 2025 To, To, Dy. General Manager The Manager – Listing, Department of Corporate Services, National Stock Exchange of India Ltd., BSE Ltd., Plot No. C/1, G Block, P. J. Towers, Dalal Street, Bandra Kurla Complex, Fort, Mumbai – 400 001 Bandra (E), Mumbai – 400 051 Ref: Scrip Code: 543322 Ref:
Slide 2: Investor Presentation Q4 & FY25
Investor Presentation Q4 & FY25
Slide 3: Disclaimer
Disclaimer The Presentation is to provide the general background information about the Company’s activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any i
Slide 4: Financial Performance Review
Financial Performance Review 3
Slide 5: Q4 FY25 Highlights
Q4 FY25 | Highlights "FY25 was our first full year under the Nirma ownership. Our overall performance has remained consistent with past years, with sustained margins, despite facing external challenges, most notably the loss in PLI revenue. The road ahead has significant opportunities for which we h
Slide 6: Q4 & FY25 Performance
Q4 & FY25 Performance Revenue EBITDA PAT EPS ( I n ₹ M illio n s) ( I n ₹ M illio n s) ( I n ₹ M illio n s) (In ₹) 31.3% 32.1% 21.3% 21.8% 28.0% 28.2% 6,496 6,418 26.9% 5,886 18.3% 18.9% 18.8% 11.57 11.18 2,085 5,366 2,008 5,069 1,419 1,370 9.10 1,650 1,115 7.99 1,446 7.78 1,429 979 953 Q4 Q1 Q2 Q3
Slide 7: P&L Highlights | Q4 & FY25
P&L Highlights | Q4 & FY25 Particulars (In ₹ Millions) Q4 FY25 Q3 FY25 QoQ Q4 FY24 YoY FY25 FY24 YoY Revenue from Operations 6,496 6,418 1.2% 5,366 21.1% 23,869 22,832 4.5% Gross Profit 3,670 3,566 2.9% 2,979 23.2% 13,061 12,812 1.9% Gross Profit (%) 56.5% 55.6% 55.5% 54.7% 56.1% Other Income 101 10
Slide 8: Healthy Return Indicators
Healthy Return Indicators ROICE (%) Fixed Assets Turnover (Times) Working Capital Days 40% 166 170 192 36% 176 34% 32% 3.3 3.4 2.9 152 2.7 103 27% 102 107 99 89 136 148 120 116 122 FY21 FY22 FY23 FY24 FY25 FY21 FY22 FY23 FY24 FY25 -43 -53 -59 -59 -72 • ROICE is tracking at ~27% – Capital employed dr
Slide 9: Robust Growth & Steady Profitability
Robust Growth & Steady Profitability Revenue EBITDA PAT EPS ( I n ₹ M i l li on s ) ( I n ₹ M illio n s) ( In ₹ M illio n s) (In ₹) EBITDA Margin PAT Margin 31.5% 31.4% 31.1% 21.6% 30.1% 30.0% 20.6% 20.3% 19.7% 39.63 18.6% 38.43 38.11 7,172 4,857 6,863 6,712 23,869 4,709 35.63 4,670 22,832 6,308 32.
Slide 10: Business Performance Review
Business Performance Review 9
Slide 11: Segmental Performance | Generic API vs CDMO
Segmental Performance | Generic API vs CDMO Generic API CDMO ( R e ve n u e I n ₹ M illio n s) ( R e ve nu e I n ₹ M illio n s) 5,966 5,941 425 434 5,354 4,846 4,739 354 300 240 Q4 FY24 Q1 FY25 Q2 FY25 Q3 FY25 Q4 FY25 Q4 FY24 Q1 FY25 Q2 FY25 Q3 FY25 Q4 FY25 • CDMO business witnessed growth of 22.6%
Slide 12: Segmental Performance | GPL vs Non-GPL
Segmental Performance | GPL vs Non-GPL GPL % of Total Revenue Non-GPL % of Total Revenue ( I n ₹ M illio n s) ( I n ₹ M illio n s) 37.2% 33.6% 33.4% 72.4% 31.1% 66.4% 27.6% 2,181 66.6% 68.9% 1,963 1,888 4,315 1,773 3,923 62.8% 4,645 1,667 3,699 3,181 Q4 FY24 Q1 FY25 Q2 FY25 Q3 FY25 Q4 FY25 Q4 FY24 Q
Slide 13: Market and Therapeutic Area Mix
Market and Therapeutic Area Mix Market Mix Therapeutic Area Mix 17% 16% 13% 18% 14% 37% 37% 35% 35% 36% 5% Others 4% 4% 6% 4% Emerging 5% 4% 4% Pain Management 8% 7% Markets 15% 14% 9% 14% 14% Diabetes 83% 84% 87% 82% 86% CNS Regulated Markets CVS 42% 38% 40% 41% 42% Q4 FY24 Q1 FY25 Q2 FY25 Q3 FY25
Slide 14: Company Overview
LIFE SCIENCES Company Overview ¢
Slide 15: Global Footprint
Global Footprint • Filed 561 DMFs and CEPs across major markets; United States, Europe, Japan, Russia, Brazil, South Korea, Taiwan, Canada, China and Australia ROW 70+ 370+ 30+ 113 143 176 10+ 19 125+ 10+ 50+ 22 88 (Brazil) India – Mix of Regulated Number of Number of customers As of March 31, 2025
Slide 16: R&D Capabilities
R&D Capabilities Cumulative Filing Status R&D Spend ( I n ₹ M illio n s) North Therapy Europe Japan Brazil Australia ROW Total % of Total Revenue America CVS 39 39 4 22 10 38 152 3.3% 3.4% CNS 41 26 8 16 2 20 113 3.0% 805 Diabetes 10 5 - 9 - 14 38 2.7% 753 Pain Management 1 2 - 4 1 9 17 652 Others 8
Slide 17: Quality Focused Manufacturing and R&D Infrastructure
Quality Focused Manufacturing and R&D Infrastructure Manufacturing Infrastructure R&D Infrastructure Annual Installed Last USFDA Location Approvals Mahape, Navi Mumbai Capacity Inspection Date USFDA, MHRA (UK), FIMEA R&D for new product (Finland), Romania (Europe) PMDA development and complex Ankl
Slide 18: Strategy Going Forward
LIFE SCIENCES Strategy Going Forward ¢
Slide 19: Strategy
Strategy Growth Levers 1 Gx API Business New product launches 2 Geographical expansion New Growth levers Focus on new markets becoming more regulated CDMO Ramp up Pursue 2nd source opportunities with top generic players Expand into complex API platforms Iron compounds Oncology & HP A
Slide 20: Future Capacity Expansion
Future Capacity Expansion Operational Expansion Type Division Location Status & Planned Capacity Timelines Brownfield API / Intermediate Ankleshwar Planned addition of ~60KL Pharma Capacity FY26 Brownfield API Dahej Planned addition of ~160KL FY26 Phase 1 – ~200 KL (Construction is in process) FY26
Slide 21: Thank You
Thank You FOR FURTHER INFORMATION CONTACT Email: complianceofficer@alivus.com ERNST & YOUNG LLP – INVESTOR RELATIONS DIWAKAR PINGLE RUNJHUN JAIN SNEHA SALIAN Email: diwakar.pingle@in.ey.com Email: runjhun.jain1@in.ey.com Email: sneha2.salian@in.ey.com CORPORATE OFFICE: REGISTERED OFFICE: T: 91 22 68